Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT06345690
Active, not recruiting Observational

VIA Disc NP Registry 3.0

NCT06345690 · tracked via the Priya Life Science USA tracker
Sponsor
VIVEX Biologics, Inc
Phase
Observational
Started
2024-02-27
Last updated
2026-05-12

Condition(s) studied

Discogenic PainBack PainBack Pain, Low

Investigational drug(s) / intervention(s)

VIA Disc NP

VIA Disc NP: VIA Disc NP - Allograft tissue injection

Study summary

Registry is to observe and trend patterns of care and outcomes for patients treated with VIA Disc NP.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: 1. Willing to sign the informed consent and deemed capable of complying with the requirements of the study protocol 2. 18 years of age or older 3. Literate, able to speak and read English, and able to complete questionnaires independently 4. Subject received a VIA Disc NP injection with 1 or more levels within 90 days of the baseline visit. Exclusion Criteria: 1. Participant did not receive VIA Disc NP injection 2. Participant is pregnant (self-reported, no special study pregnancy testing needed). 3. Any contraindications as noted in the VIA Disc NP Instructions for Use 4. Previous treatment with VIA Disc NP

Primary outcome measure(s)

  • Numeric Pain Rating Scale (NPRS) — 1, 3, 6, & 12 months
    Change in Numeric Rating Scale (NRS) scores. Eleven point pain scale used for patient self-reporting of back pain, which ranges from 0 (no pain) to 10 (the worst pain imaginable).
  • Oswestry Disability Index (ODI) — 1, 3, 6, & 12 months
    Change in scores from Oswestry Disability Index (ODI). An index comprising of ten categories of function to quantify disability due to back pain.
  • Patient Satisfaction — 1, 3, 6, & 12 months
    Patient reported assessment of treatment regarding their experience with the procedure. Four different responses, which range from Not at all satisfied (worst) to Extremely Satisfied (best).
  • Frequency of Pain Medication Use — 1, 3, 6, & 12 months
    Assesses the frequency and type of pain medication administered to participants at baseline and follow-up visits scheduled at 1, 3, 6, and 12 months. Data will be collected to track changes in pain medication usage over time.

Trial sites (24)

FacilityCityRegionStatus
Mocek Spine Little Rock Arkansas
MD Pain Englewood Colorado
Western Rockies Interventional Pain Grand Junction Colorado
Premier Spine and Pain Institute Thornton Colorado
The Orthopedic Institute Gainesville Florida
Raso Pain Center Jupiter Florida
Interventional Spine Care of the Palm Beaches West Palm Beach Florida
Horizon Clinical Research Jasper Georgia
The Orthopedic Research Foundation, Inc. Fishers Indiana
Interventional Pain Specialists - Pain Clinic Opelousas Louisiana
Paradigm Health System Slidell Louisiana
Premier Pain Solutions Asheville North Carolina
Comprehensive Pain Consultants of the Carolinas Hendersonville North Carolina
Crystal Coast Pain Management Morehead City North Carolina
Crystal Coast Pain Management New Bern North Carolina
Align Interventional Pain Edmond Oklahoma
Atlantic Coast Spine & Pain Conway South Carolina
Renew Pain Solutions Greenville South Carolina
Specialists in Pain Managment Chattanooga Tennessee
Freedom Spine Boerne Texas
Corpus Chrisi Pain Medicine Corpus Christi Texas
Advanced Spine and Pain Center San Antonio Texas
Pain and Wellness Institute of Texas Spring Branch Texas
Precision Spine Care Tyler Texas

More VIVEX Biologics, Inc. trials in the USA

Clinical Trial Evaluating the Safety and Efficacy of Nucleus Pulposus Allograft in Participants With Degenerative Disc Disease Recruiting

Other trials for the same condition

Post Marketing Study of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers Mixed With Autograft in Patients Undergoing Posterolateral Lumbar Fusion Active, not recruiting
HFIT Versus TENS Study for Chronic Low Back and Knee Pain Active, not recruiting
Safety and Efficacy of the BTL-043 and BTL-899 Devices in Alleviating Back Pain Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06345690 on ClinicalTrials.gov ↗ ← All trials in the USA